Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSX: ATE) announced that the Company’s request for an extension of its previously announced stay of proceedings under the Companies’ Creditors Arrangement Act (the “CCAA”) was heard before the Ontario Superior Court of Justice (Commercial List) (the “Court”) on April 18, 2024 and the decision was reserved.

On April 22, 2024, the Court issued its decision terminating CCAA proceedings and appointing FTI Consulting Canada Inc. as receiver of Antibe.

The Company also announced that Roderick Flower, Robert Hoffman, Dan Legault, Walt Macnee and Yung Wu have resigned from Antibe’s Board of Directors. In addition, the Company today received notification from the TSX that it will be delisting Antibe’s common shares from the TSX effective as of May 24, 2024.

Antibe Therapeutics Inc. Christina Cameron VP Investor Relations +1 416-577-1443 christina@antibethera.com

Antibe Therapeutics (TSX:ATE)
過去 株価チャート
から 4 2024 まで 5 2024 Antibe Therapeuticsのチャートをもっと見るにはこちらをクリック
Antibe Therapeutics (TSX:ATE)
過去 株価チャート
から 5 2023 まで 5 2024 Antibe Therapeuticsのチャートをもっと見るにはこちらをクリック